Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 13/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | TSPO | P30536 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8773288 | 0.85 | CYP1A1 (0.40) | FFAR1FFAR4CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL8770919 | 0.82 | CYP1A1 (0.43) | FFAR1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL15132376 | 0.81 | FFAR1 (0.43) | FFAR1FFAR4TSPODRD3 | |
| SCHEMBL29860734 | 0.81 | FFAR1 (0.40) | FFAR1FFAR4TSPODRD3 | |
| SCHEMBL22391732 | 0.81 | FFAR1 (0.40) | FFAR1FFAR4TSPODRD3 | |
| SCHEMBL8773234 | 0.79 | CYP1A1 (0.41) | FFAR1FFAR4CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL8772677 | 0.78 | CYP1A1 (0.40) | FFAR1FFAR4CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL1162443 | 0.77 | FFAR1 (0.45) | FFAR1FFAR4NR3C1PGRNR3C2 | |
| SCHEMBL1164992 | 0.77 | FFAR1 (0.38) | FFAR1FFAR4 | |
| SCHEMBL29518342 | 0.77 | FFAR1 (0.45) | FFAR1FFAR4NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023066356-A1 | COMPOUND AS GLP-1 RECEPTOR AGONIST AND USE THEREOF | 盛世泰科生物医药技术(苏州)有限公司 | 2023-04-27 | — | — | WO | disclosed |
| CN-116003393-A | Compounds as GLP-1 receptor agonists and uses thereof | 盛世泰科生物医药技术(苏州)有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | NAT1, NQO2, NOX1 | FFAR1 2371/4885FFAR4 3454/4885CYP1A1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.